BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 37189081)

  • 1. Cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non-small cell lung cancer: a modelling approach.
    Hui W; Song R; Tao H; Gao Z; Zhu M; Zhang M; Wu H; Gong D; Zhang X; Cai Y
    BMC Cancer; 2023 May; 23(1):442. PubMed ID: 37189081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
    Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
    Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of first-line immunotherapies for advanced non-small cell lung cancer.
    Yang SC; Ou HT; Su WC; Wang SY
    Cancer Med; 2023 Apr; 12(7):8838-8850. PubMed ID: 36653947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC.
    Chen P; Wang X; Zhu S; Li H; Rui M; Wang Y; Sun H; Ma A
    Front Public Health; 2022; 10():956792. PubMed ID: 36016894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy.
    Pang LL; Gan JD; Huang YH; Liao J; Zhuang WT; Ali WA; Hong SD; Zhang L; Fang WF
    BMC Cancer; 2023 Jan; 23(1):72. PubMed ID: 36670414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States.
    Criss SD; Mooradian MJ; Watson TR; Gainor JF; Reynolds KL; Kong CY
    JAMA Netw Open; 2019 Sep; 2(9):e1911952. PubMed ID: 31553470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer.
    Aziz MIA; Tan LE; Tan WHG; Toh CK; Loke LPY; Pearce F; Ng K
    J Med Econ; 2020 Sep; 23(9):952-960. PubMed ID: 32462958
    [No Abstract]   [Full Text] [Related]  

  • 10. Immune checkpoint inhibitors
    Liu S; Dou L; Li S
    Therap Adv Gastroenterol; 2024; 17():17562848241233134. PubMed ID: 38425370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma.
    Liu L; Wang L; Chen L; Ding Y; Zhang Q; Shu Y
    Front Immunol; 2023; 14():1092385. PubMed ID: 36756110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC).
    Ondhia U; Conter HJ; Owen S; Zhou A; Nam J; Singh S; Abdulla A; Chu P; Felizzi F; Paracha N; Sangha R
    J Med Econ; 2019 Jul; 22(7):625-637. PubMed ID: 30836031
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China.
    Liao W; Huang J; Hutton D; Li Q
    J Med Econ; 2019 Apr; 22(4):344-349. PubMed ID: 30646794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC.
    Wan N; Zhang TT; Hua SH; Lu ZL; Ji B; Li LX; Lu LQ; Huang WJ; Jiang J; Li J
    Cancer Med; 2020 Mar; 9(5):1683-1693. PubMed ID: 31945265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost-effectiveness analysis.
    Wan X; Luo X; Tan C; Zeng X; Zhang Y; Peng L
    Cancer; 2019 Oct; 125(20):3526-3534. PubMed ID: 31287562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis of sintilimab + chemotherapy versus camrelizumab + chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China.
    Rui M; Fei Z; Wang Y; Zhang X; Ma A; Sun H; Li H
    J Med Econ; 2022; 25(1):618-629. PubMed ID: 35475459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma.
    Zhang X; Wang J; Shi J; Jia X; Dang S; Wang W
    JAMA Netw Open; 2021 Apr; 4(4):e214846. PubMed ID: 33825837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of atezolizumab plus chemotherapy as first-line treatment for patients with advanced nonsquamous non-small-cell lung cancer in China.
    Shang F; Zhang B; Kang S
    Expert Rev Pharmacoecon Outcomes Res; 2023 Mar; 23(3):337-343. PubMed ID: 36655382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China.
    Yang Z; Zhu Y; Xiang G; Hua T; Ni J; Zhao J; Lu Y; Wu Y; Chang F
    Expert Rev Pharmacoecon Outcomes Res; 2021 Oct; 21(5):1061-1067. PubMed ID: 33682554
    [No Abstract]   [Full Text] [Related]  

  • 20. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
    Dafni U; Tsourti Z; Vervita K; Peters S
    Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.